Impact of antibiotics exposure in the peri-CAR period on patient outcomes

Our goal is to advance a better understanding of antibiotics in CAR T-cell therapy by evaluating the impact of antibiotics peri-CAR on clinical outcomes including toxicity, remission, and survival. Our study primarily focuses on usage of the following anaerobic antibiotics: Amoxicillin-clavulanate, Ampicillin-sulbactam, Clindamycin, Ertapanem, Imipenem-cilastatin, Linezolid, Meropenem, Metronidazole, Piperacillin-tazobactam, and Tedizolid. Data was collected from Stanford University, Duke University, and University of North Carolina.